A novel biomarker signature combining PAF and CME predicts chronic pain risk, linking brain activity to individual pain ...

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

Predicting who will transition from acute to chronic pain is the “holy grail” of pain neuroscience. A novel biomarker ...

A novel biomarker signature that assessed cortical activity predicted individual pain sensitivity, the PREDICT validation ...

Chicago, IL, USA), Tony discusses how they used opti-ox to generate nociceptor sensory neurons that respond efficiently to stimuli, providing a potential pain model that could help develop more ...

A novel biomarker signature can classify pain sensitivity, offering potential for early intervention and improved chronic ...

6 Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health Sciences and Keele Clinical Trials Unit, Keele University, Staffordshire, UK The need for pain to be avoided ...

Scientists at Google DeepMind and the London School of Economics and Political Science (LSE) are trying to figure out how to determine if artificial ...

"The combination of biomarker accuracy, reproducibility, reliability, and pain model validity suggests high potential for clinical translation, particularly in predicting the transition from acute ...